LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 01, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in the following upcoming conferences in May:
- 2019 American Academy of Neurology (AAN) Annual Meeting, May 4 – 10, Philadelphia, PA.
- uniQure will deliver multiple data presentations at the meeting covering the Company’s advancements for its gene therapy candidates in Huntington’s disease and Spinocerebellar Ataxia Type 3.
- uniQure will deliver multiple data presentations at the meeting covering the Company’s advancements for its gene therapy candidates in Huntington’s disease and Spinocerebellar Ataxia Type 3.
- Canaccord Genuity Gene Therapy Manufacturing Summit, May 9, Boston, MA.
- Scott McMillan, chief operating officer at uniQure, will be presenting on Thursday May 9th at 10:00 a.m. ET, followed by the AAV Manufacturing panel discussion at 10:30 a.m. ET.
- Scott McMillan, chief operating officer at uniQure, will be presenting on Thursday May 9th at 10:00 a.m. ET, followed by the AAV Manufacturing panel discussion at 10:30 a.m. ET.
- Hemostasis & Thrombosis Research Society 2019 Scientific Symposium, May 9 - 11, New Orleans, LA.
- Adam Giermasz, M.D., Ph.D., investigator of the trial at UC Davis, CA, will present 26 weeks of follow-up data on the three patients in the AMT-061 Phase 2b study.
| Title: | A Single Infusion of AMT-061 (AAV5-Padua hFIX) is Safe and Effective in Adults with Hemophilia B: Interim Results from Dose-Confirmation Phase 2b Trial (#44) |
| Session: | Poster Session 1 |
| Date & Time: | Friday, May 10, 4:45 – 5:55 p.m. CT |
| Location: | St. Charles Ballroom |
Italian Association of Huntington’s Disease Roma 2019 Meeting, May 18, Rome, Italy.
- Astrid Valles-Sanchez, senior scientist at uniQure will be presenting “Development of a microRNA-based gene therapy for Huntington’s disease” on Saturday, May 18th at 10:30 a.m. CET.
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and other severe genetic diseases. www.uniQure.com
uniQure Contacts
For Investors:
Maria E. Cantor
Direct: 339-970-7536
Eva M. Mulder
Direct: +31 20 240 6103
For Media:
Tom Malone
Direct: 339-970-7558